We are live on ! Find out more
PFM

Privium Fund Management Portfolio holdings

AUM $544M
1-Year Est. Return 72.49%
This Fund
S&P 500
This Quarter Est. Return
-13.18%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$480M
AUM Growth
-$62.8M
Cap. Flow
+$19.4M
Cap. Flow %
4.03%
Top 10 Hldgs %
63.98%
Holding
64
New
7
Increased
24
Reduced
17
Closed
4

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$10.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.38M
3
DNLI icon
Denali Therapeutics
DNLI
+$5.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.16M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.88M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.47M
2
MRK icon
Merck
MRK
+$3.85M
3
TSLA icon
Tesla
TSLA
+$2.68M
4
ARWR icon
Arrowhead Research
ARWR
+$1.98M
5
VZLA
Vizsla Silver
VZLA
+$1.12M

Sector Composition

Rank Sector Weight
1 Healthcare 33.85%
2 Consumer Discretionary 24.98%
3 Technology 24.21%
4 Financials 8.49%
5 Communication Services 6.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$30B
$4.04M 0.84%
+12,222
New +$4.16M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.48B
$3.39M 0.71%
173,516
– –
KRYS icon
28
Krystal Biotech
KRYS
$9.67B
$2.89M 0.6%
11,170
-1,000
-8% -$266K
ABEV icon
29
Ambev
ABEV
$43B
$2.77M 0.58%
948,558
-114,616
-11% -$328K
ZLAB icon
30
Zai Lab
ZLAB
$2.93B
$2.49M 0.52%
132,189
– –
BNTX icon
31
BioNTech
BNTX
$23.1B
$2.4M 0.5%
27,000
-6,300
-19% -$647K
ENGN icon
32
enGene Therapeutics
ENGN
$115M
$2.4M 0.5%
352,087
– –
CRSP icon
33
CRISPR Therapeutics
CRSP
$5.11B
$2.04M 0.42%
42,874
– –
MGTX icon
34
MeiraGTx Holdings
MGTX
$1.23B
$1.84M 0.38%
212,112
+12,112
+6% +$92K
WVE icon
35
Wave Life Sciences
WVE
$1.05B
$1.75M 0.36%
241,010
+48,000
+25% +$625K
STOK icon
36
Stoke Therapeutics
STOK
$2.02B
$1.63M 0.34%
50,000
-5,000
-9% -$164K
FDMT icon
37
4D Molecular Therapeutics
FDMT
$598M
$1.59M 0.33%
170,256
-39,744
-19% -$346K
BEAM icon
38
Beam Therapeutics
BEAM
$2.69B
$1.52M 0.32%
63,982
-7,518
-11% -$209K
MRNA icon
39
Moderna
MRNA
$25.1B
$1.52M 0.32%
29,994
-19,600
-40% -$914K
PFE icon
40
Pfizer
PFE
$152B
$1.48M 0.31%
52,679
+14,929
+40% +$397K
LXEO icon
41
Lexeo Therapeutics
LXEO
$395M
$1.18M 0.25%
205,000
+12,450
+6% +$88.2K
RNAC icon
42
Cartesian Therapeutics
RNAC
$264M
$1.1M 0.23%
179,114
+6,614
+4% +$47.1K
MOH icon
43
Molina Healthcare
MOH
$11B
$1.09M 0.23%
+8,140
New +$1.3M
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.88B
$1M 0.21%
46,000
+3,000
+7% +$58.1K
SLB icon
45
SLB Ltd
SLB
$79.4B
$948K 0.2%
18,451
-20,354
-52% -$988K
RCKT icon
46
Rocket Pharmaceuticals
RCKT
$363M
$867K 0.18%
242,146
+72,000
+42% +$286K
HIMS icon
47
Hims & Hers Health
HIMS
$6.73B
$830K 0.17%
40,000
– –
TSHA icon
48
Taysha Gene Therapies
TSHA
$1.87B
$813K 0.17%
181,900
+17,000
+10% +$79K
NOV icon
49
NOV
NOV
$7.54B
$791K 0.16%
42,026
-11,100
-21% -$208K
RIG icon
50
Transocean
RIG
$6.57B
$707K 0.15%
106,604
-33,000
-24% -$186K
1
2
3

Similar funds

BCM
Brasada Capital Management Houston, Texas $545M AUM 18.58% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $547M AUM 20.34% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $547M AUM 64.58% 1-Year Est. Return
FMC
FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return
WCP
Wick Capital Partners Wayne, Pennsylvania $548M AUM 16.95% 1-Year Est. Return
CM
CoreCommodity Management Stamford, Connecticut $538M AUM 71.97% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
KI
Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return

Privium Fund Management's Q1 2026 Portfolio in Review

As of Q1 2026, Privium Fund Management held 64 positions worth $480M, down 12% from $543M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Privium Fund Management deployed $19.4M of net new capital in Q1 2026, opening 7 new positions and adding to 24 existing holdings. Its largest new stake was Esperion Therapeutics: 3,299,441 shares worth $9.04M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Biogen, an estimated $5.47M trimmed.

  • Privium Fund Management's largest Q1 2026 buy was Esperion Therapeutics: 3,299,441 shares worth $9.04M.
  • Privium Fund Management added most to Ionis Pharmaceuticals in Q1 2026, an estimated $3.88M increase.
  • Privium Fund Management's biggest Q1 2026 reduction was Biogen, cutting an estimated $5.47M.
  • Privium Fund Management fully exited Merck in Q1 2026, selling an estimated $3.85M.
  • Privium Fund Management's ten largest holdings make up 64% of its $480M portfolio in Q1 2026.
  • Privium Fund Management opened 7 new positions and closed 4 in Q1 2026.
  • Privium Fund Management's portfolio value fell 12% quarter-over-quarter to $480M.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.